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ABSTRACT
Two independent regions within HNF1B are consistently identified in prostate 
and ovarian cancer genome-wide association studies (GWAS); their functional roles 
are unclear. We link prostate cancer (PC) risk SNPs rs11649743 and rs3760511 with 
elevated HNF1B gene expression and allele-specific epigenetic silencing, and outline 
a mechanism by which common risk variants could effect functional changes that 
increase disease risk: functional assays suggest that HNF1B is a pro-differentiation 
factor that suppresses epithelial-to-mesenchymal transition (EMT) in unmethylated, 
healthy tissues. This tumor-suppressor activity is lost when HNF1B is silenced by 
promoter methylation in the progression to PC. Epigenetic inactivation of HNF1B in 
ovarian cancer also associates with known risk SNPs, with a similar impact on EMT. 
This represents one of the first comprehensive studies into the pleiotropic role of a 
GWAS-associated transcription factor across distinct cancer types, and is the first to 
describe a conserved role for a multi-cancer genetic risk factor.
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INTRODUCTION
Genome-wide association studies (GWAS) and 
fine-mapping have identified several distinct variants 
within the hepatocyte nuclear factor 1b (HNF1B) gene 
associated with increased risk of prostate cancer [1-8] and 
high-grade serous and clear cell epithelial ovarian cancer 
(OC) [9, 10]. It has also been associated with both type 
I and II endometrial cancer risk in a large meta-analysis 
[11]. HNF1B has three main regions of risk association 
(Figure 1) in which the four most significant risk variants 
for these two cancer types lie: rs11649743 in linkage block 
7, rs4430796 and rs7501939 (all prostate) are in strong 
linkage disequilibrium in region 8 (r2 = 0.764) (Table 
1), with the most significant SNP for serous invasive 
ovarian cancer risk rs757210 immediately adjacent. 
Prostate cancer (PC) risk SNP rs3760511 is within 1kb 
of the transcription start site (TSS) and was identified in 
a GWAS of four European populations; although not the 
most statistically significant marker, the rs-3760511-C 
allele is associated with an odds ratio of 1.16 [2]. 
HNF1B encodes a transcription factor with a central 
role in vertebrate development and embryonic survival 
[12]. Rare exonic mutations result in uro-genital defects, 
pancreatic atrophy and maturity onset diabetes of the 
young 5 (MODY5) [13], but its role in tumor development 
is yet to be described. Based on the identification of several 
cancer-associated SNPs within HNF1B, we aimed to define 
the function of HNF1B in this context. In vitro functional 
assays together with gene expression data from matched 
cancer and non-cancer patient tissue suggest that HNF1B 
exerts a tumor-suppressive effect when over-expressed in 
cancer cells. This protective effect is lost following DNA 
silencing by promoter methylation in the development of 
prostate cancer. To determine whether HNF1B expression 
can act as a brake on cancer development, we assessed 
the phenotypic effects of ectopic HNF1B over-expression 
in cancer cells, and observed a reversal of epithelial-to-
mesenchymal transition (EMT). This represents one of the 
first comprehensive studies to demonstrate a functional 
role for a GWAS-identified target from prostate cancer, 
and to show that a similar mechanism operates in other 
cancer types. Our data support an emerging hypothesis 
that common functional mechanisms underlie the biology 
of neoplastic development at pleotropic risk loci identified 
by GWAS [14]. This work highlights the potential 
relevance of GWAS-findings across different but related 
complex disease types, providing a starting point for other 
functional follow-up studies and further collaborations. 
RESULTS
HNF1B expression correlates with risk SNP 
genotype in prostate tissues
To determine whether any of the known, significant 
PC risk SNPs correlated with HNF1B expression levels, 
we genotyped each SNP in 65 British patients, and 
compared these to mRNA levels of HNF1B in tumor 
tissue and, where possible, matched non-tumor tissue 
from the same individuals. We found a significant 
correlation between rs11649743-G and elevated HNF1B 
levels in tumor tissue (n = 66) (p = 0.038) (Figure 2A), 
corresponding to the identification of the G-allele as the 
risk allele for PC [4]. In a smaller cohort of laser-captured 
micro-dissected prostate tumor tissue from 36 Danish 
patients, we found a significant correlation between risk 
SNP rs3760511-G [2] and elevated HNF1B levels (p = 
0.018) (Figure 2B). These two SNPs are only in weak LD 
(Figure 1), and so these could represent distinct expression 
quantitative trait loci (eQTL) signals. Alternatively, they 
may interact at the chromatin level when HNF1B executes 
its functions as a transcription factor, and so together 
they could effectively constitute one signal. We found no 
association between rs4430796 (in LD with rs7501939; r2 
= 0.764) and HNF1B expression levels, which may be due 
to our relatively small sample size compared to Grisanzio 
et al. (2012)[15], who identified a correlation between 
rs4430796 and HNF1B expression levels in benign tissues 
in three ethnic cohorts – European, Japanese and African 
Americans (total n = 407).
HNF1B promoter methylation correlates with 
prostate cancer risk SNP genotype
Promoter methylation plays a key role in 
transcriptional regulation, with the presence of methyl 
groups on cytosine bases at gene promoters essentially 
silencing gene expression. The HNF1B promoter 
harbors a CpG island that is a known target of epigenetic 
inactivation in high-grade serous (HGS) OC, as well as 
ovarian, colorectal, gastric and pancreatic cell lines [16, 
17]. This CpG island has not previously been reported 
as a methylation target in PC (http://pubmeth.org). To 
determine whether epigenetic inactivation could play a 
role in regulating HNF1B expression levels in prostate 
cancer, we compared methylation levels at the HNF1B 
promoter between cancer and matched non-cancer 
samples in two cohorts (see Methods). Tumor tissues show 
significant hyper-methylation at this promoter compared 
to matched non-tumor tissues in both British (n = 59, p = 
0.0076; Figure 3Ai) and Danish prostate cancer patients (n 
= 21, p = 0.0003; Figure 3Aii, blue dots). TCGA prostate 
cancer methylation data further confirm elevated HNF1B 
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promoter methylation in tumor compared to normal 
tissue (Supplementary Figure 1). Hypermethylation at 
this promoter is also associated with reduced HNF1B 
expression in these same samples (Figure 3A-iii). 
In addition, PC risk SNP rs11649743-G was 
associated with significantly lower levels of HNF1B 
promoter methylation in tumor tissues in British samples 
(p = 0.0296; Figure 3B-i), while promoter region risk 
allele rs3760511-G associated with reduced HNF1B 
promoter methylation in the Danish cohort of 21 pairs of 
laser-capture micro-dissected (LCM) tumor and normal 
and adjacent-normal samples (p = 0.0283; Figure 3B-ii).
Essentially, two established, independent PC risk 
alleles variants – rs11649743-G and rs3760511-G – are 
both associated with reduced promoter methylation at 
HNF1B, and simultaneously increased HNF1B expression 
in two different clinical prostate cohorts, suggesting a 
plausible mechanism for this observation. We found no 
association between any other PC risk SNP tested and 
promoter methylation in either cohort (Supplementary 
Figure 2A and 2B.). 
HNF1B has functional roles significant in prostate 
cancer
To identify biological pathways regulated by 
HNF1B in the context of cancer, we generated stable 
cell lines over-expressing HNF1B (see Methods). PC3 
and DU145 are prostate cancer cells derived from bone 
and dura mater metastases (aggressive tumours), while 
PNT2a cells originate from normal prostate epithelial 
cells. Total RNA from PC3 cell line expressing empty 
vector (PC3-EV) and derived PC3-HNF1B cells was 
assayed on Illumina HT12 gene expression arrays, since 
this was the cell line with the highest over-expression 
of HNF1B (Supplementary Figure 3A-C). In total, 60 
down- and 150 up-regulated genes were identified from 
two biological replicates, and used in subsequent analyses 
(Methods, Supplementary methods and Supplementary 
Table 1). Gene ontology (GO) enrichment analysis of 
the DEG following over-expression of HNF1B in this 
prostate cancer model suggested that biological pathways 
in cellular movement, growth and proliferation were over-
represented (Supplementary Figure 4). 
Over-expression of HNF1B corresponded with 
Figure 1: Overall LD within HNF1B highlighting eight regions (black triangles), with rs11649743 in region 7 and 
rs4430796, rs7501939 and rs3760511 in region 8. Ovarian cancer risk SNP rs757210 lies immediately adjacent to region 8. D′ 
values were derived from 1000 genomes project CEU data (http://www.1000genomes.org/), and linkage plots generated in Haploview 
using 95 % confidence intervals (Gabriel 2002).
Oncotarget4www.impactjournals.com/oncotarget
a marked reduction in proliferation in PC3 and DU145 
prostate cancer cells compared to empty vector (EV) 
controls (p < 0.0001, Figure 4A-i); no effect was observed 
in normal prostate PNT2a model (p = 0.6629; Figure 4A-
ii), while viability was unaffected in all cell lines (Figures 
4A-iii and 4A-iv) HNF1B over-expression also led to a 
decrease in the rate of cell migration in prostate cancer 
models (p < 0.0001) (Figure 4B-i), but HNF1B levels had 
no effect on cell migration in PNT2a cells (p = 0.7771; 
Figure 4B-ii). Invasiveness of normally highly metastatic 
PC3 and DU145 cells was significantly reduced on 
over-expression of HNF1B (p < 0.0001 and p < 0.0003, 
respectively) (Figure 4C-i), but HNF1B expression had no 
effect on the invasive potential of normal prostate cells (p 
= 0.5358; Figure 4-Cii). In addition, clonogenic potential 
was significantly reduced in PC3-HNF1B and DU145-
HNF1B cells compared to EV (p = 0.01 and p < 0.0001 
respectively) (Figure 4D-i), but was unaffected in PNT2a 
cells (p = 0.2784, Figure 4D-ii). 
Over-expression of HNF1B also effected an obvious 
change in morphology. PC3-EV cells normally have an 
elongated mesenchymal morphology, but PC3-HNF1B 
cells acquired a flattened, epithelial-like morphology 
(Supplementary Figure 5A-C), an effect also observed in 
endometrial cells [17]. Paxillin is a major component of 
focal adhesion complexes and a ligand of integrin, and 
participates in cell adhesion-mediated signal transduction. 
As such, it has an important role in the regulation of cell 
shape and movement, and the morphological changes 
observed were associated with concomitant changes 
in the localization of the adaptor protein paxillin in 
these cells (Supplementary Figure 6A-F), as well as in 
DU145-HNF1B cells compared to DU145-EV controls 
(Supplementary Figure 6G-L). Neither cell line normally 
exhibits large peripheral adhesions; however, both PC3 
and DU145 cells over-expressing HNF1B displayed large, 
prominent peripheral paxillin-associated adhesions. These 
changes were not evident in normal prostate PNT2a-EV 
or PNT2a-HNF1B cells (Supplementary Figure 6M-
R), which both displayed very few paxillin-associated 
adhesions. A reduction in proliferation can affect some 
trans-well migration assays, but DU145 cells with larger 
paxillin-associated adhesions have been shown to migrate 
more slowly [18], so this is more likely to be the reason 
HNF1B over-expressing cells migrate less than their EV 
counterparts. The redistribution of paxillin into large 
peripheral adhesions was independent of total paxillin 
levels, which were comparable between PC3-EV and 
PC3-HNF1B, and DU145-EV and DU145-HNF1B cells 
(Supplementary Figure 7A and B). 
The changes in localization of paxillin within the 
cell together with alterations in migration potential and 
prominent clustering at the cell periphery when HNF1B is 
over-expressed in prostate cancer models strongly suggest 
that loss of HNF1B expression has a fundamental role in 
EMT. 
HNF1B-related gene networks are enriched in 
clinical cancer studies
Using gene set enrichment analysis (GSEA)[19] we 
compared the 210-gene signature (Supplementary Table 
1) associated with HNF1B over-expression in vitro, with 
gene expression data from five clinical prostate cancer 
studies, [20-24] to identify key genes related to functional 
phenotypes observed. The HNF1B gene signature was 
significantly enriched in four of five prostate cohorts 
(Supplementary Table 2 & Supplementary Figure 8A-D). 
Leading edge analysis in each cohort identified a subset 
of 129 key genes driving this enrichment (Supplementary 
Table 3). Pathway analysis suggested that chemotaxis and 
integrin- and cadherin-mediated cell adhesion were the 
most functionally relevant processes (GeneGo Metacore; 
Supplementary Figure 9), with two genes present in every 
sample type comparison (e.g. benign vs. tumor) across all 
Figure 2: Association between genotype and increased gene expression at rs11649743 with HNF1B levels in prostate 
tumor tissue, but not benign (Kruskal-Wallis p = 0.038) in British samples (A), between rs3760511-G and HNF1B 
levels in laser-capture micro-dissected Danish prostate tumor samples (Kruskal-Wallis p = 0.018) (B).
Oncotarget5www.impactjournals.com/oncotarget
studies - FLRT3 and SLC14A1. 
Both targets are co-expressed with HNF1B in 
clinical prostate samples, and in each case we found 
elevated levels associated with relapse-free survival (p = 
0.00025 and p = 0.00026, respectively) (Supplementary 
Figure 10 A-B) [21]. This mirrors the association reported 
by Glinsky et al., (2004), where increased levels of 
HNF1B were significantly associated with improved 
prognosis (p = 0.0093) in a primary prostate tumor 
expression data set (Supplementary Figure 10 C) [24]. 
mRNA levels of FLRT3 and SLC14A1 also showed a 
stepwise reduction from benign to primary prostate tumor 
and metastatic samples in other clinical prostate datasets 
(Supplementary Figure 11)[20-22, 25]. 
Mechanistic role of HNF1B
Using quantitative RT-PCR, we subsequently 
confirmed over-expression of novel targets FLRT3 and 
SLC14A1 and two known HNF1B target genes [26] in 
PC3-HNF1B and DU145-HNF1B cells, but not in PNT2a 
cells despite significant over-expression of HNF1B in this 
model (Supplementary Figure 12 A-E). Finally, chromatin 
immunoprecipitation (ChIP) for HNF1B in PC3-HNF1B 
cells followed by qPCR also showed enrichment of FLRT3 
and SLC14A1, indicating a direct interaction between 
HNF1B transcription factor at these target genes at the 
chromatin level (Supplementary Figure 13). This suggests 
that epigenetic inactivation of HNF1B could bring 
about the phenotypic changes observed in the cell-based 
Figure 3: Methylation at the HNF1B promoter is significantly higher in prostate tumor tissues compared to matched 
benign in British (t-test p = 0.0076) (A) and Danish samples (B) (ranksum t-test; blue spots indicate statistical 
significance at the corresponding CpG probe). The significance threshold p < 0.05 (log
10
(p) > 1.301) is indicated by the green 
line. Ovarian cancer risk SNP rs757210 is also associated with HNF1B promoter methylation (pink spots) in 231 HGS cases (see also 
Supplementary Table 7). Histone modifications typical of active promoters – H3K4Me1, H3K4Me3 and H3K27Ac – overlap with the 
transcription start site, both small and large CpG islands and risk SNP rs3760511 (UCSC Genome browser, hg19). Figure 3Aiii. Increased 
methylation at HNF1B promoter correlates strongly with reduced levels of HNF1B expression prostate tissue (TCGA data). Pink spots 
= tumor; blue spots = matched normal tissue. Figure 3-Bi. Prostate cancer risk allele rs11649743-G is associated with reduced levels 
of HNF1B promoter methylation in tumor tissue, but not benign tissue in British samples (p = 0.0296), while risk allele rs3760511-G is 
associated with reduced levels of HNF1B methylation (p = 0.0283) in 21 pairs of Danish prostate cancer samples (3B-ii).
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Figure 4: The differential effects of HNF1B in cancer and normal prostate cellular contexts. Over-expression of HNF1B 
was associated with a reduction in rate of proliferation in prostate cancer lines PC3 and DU145 compared to empty vector (4A-i), but had 
no effect in normal PNT2a cells (4A-ii). No effect on viability on any cell line was observed (4A-iii, iv). HNF1B over-expression also 
correlated with a reduction in cell migration in PC3 and DU145 cells (p < 0.0001)(4B-i), but had no effect on cell migration in normal 
PNT2a prostate cells (p = 0.7771; 4B-ii ). The invasiveness of PC3 and DU145 cancer cells was also significantly reduced with over-
expression of HNF1B (p < 0.0001 and p < 0.0003, respectively; Figure 4C-i). No difference was seen in normal PNT2a cells (p = 0.5358; 
Figure 4Cii). Clonogenic potential was significantly reduced in cancer models PC3 and DU145 over-expressing HNF1B (p = 0.01 and p < 
0.0001 respectively) (Figure 4D-i), but showed no change in the PNT2a model (p = 0.2784, Figure 4D-ii). 
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functional assays via these genes. 
FLRT3 is a member of the fibronectin leucine-rich 
transmembrane protein family, is expressed at the cell 
surface and has an established role in the regulation of 
FGF receptor signaling [27] and cadherin-mediated cell 
adhesion and morphogenesis [28, 29]. Our functional 
and bioinformatic analyses support this, and suggest 
that candidates associated with these processes in 
particular may be relevant to the effects of HNF1B in 
a cancer context. SNP variants within SLC14A1 have 
been associated with urinary bladder cancer risk [30], 
and identified as a potential biomarker in prostate cancer 
[31]. SLC14A1 encodes urea transporter B (UT-B), 
which facilitates the clearance of urea (metabolized from 
L-arginine) from cells. The loss of this transporter in 
bladder results in the accumulation of urea and reduced 
expression of arginase I [32], with a concomitant reduction 
in levels of ornithine and polyamines, and an increase in 
nitric oxide (NO) production. This makes cells vulnerable 
to DNA damage, with DNA-damaging reactive NO up-
regulated [32] and DNA-stabilising polyamines down-
regulated [33]. Interestingly, an eQTL at prostate cancer 
risk locus SLC22A3 (encoding polyamine transporter 
OCT-3) was recently reported [15], with the PC risk allele 
associated with lower levels of SLC22A3 in prostate 
tissues, and reduced viability in vitro [15].
HNF1B has similar functions and mechanism in 
ovarian cancer
HNF1B is part of a five-gene expression signature 
predictive of relapse in PC patients [24], and is also a 
biomarker that can distinguish clear cell OC from other 
subtypes[34]. Different SNPs in HNF1B are associated 
with each disease [9, 17, 35] and different subtypes of OC 
[9, 17, 36]. Since the rs757210 OC risk-associated SNP 
is in LD with key prostate cancer risk SNPs (r2 = 0.739 
with rs7501939; r2 = 0.543 with rs4430796) (Table 1), we 
tested whether we could re-capitulate our key findings in 
an ovarian context. 
Firstly, we found similar pathways relating to 
extra-cellular matrix re-modelling and cellular adhesion 
enriched in an OC model, following shRNA knock-
down of HNF1B in RMG2 ovarian cancer cells (GEO, 
GSE37290) (Supplementary Figure 14 & Methods). In 
addition, the 210-gene signature associated with HNF1B 
over-expression in prostate was enriched in two clinical 
OC cohorts [37] [38] (Supplementary Figure 15), where 
FLRT3 was identified in the leading edge gene set in each 
case (Supplementary Tables 4 & 5). SLC14A1 was only 
marginally significant. 
We compared the prostate (129) and ovarian (45) 
leading edge gene, and identified 37 genes common to 
both diseases (Supplementary Figure 16A; Supplementary 
Table 6). Chemotaxis and cadherin-mediated adhesion to 
ECM are key biological processes related to this gene set 
(Supplementary Figure 16B), which is altered (amplified/
deleted/mutated) in 72% of 246 PC cases and 82% 316 OC 
cases, based on The Cancer Genome Atlas (TCGA) data. 
None is a known cancer gene (http://cancer.sanger.ac.uk/
cancergenome/projects/cosmic/). FLRT3 is most strongly 
co-expressed with tumor suppressor gene TP63 and 
angiogenesis regulator gene NTN4 (Pearson correlation r 
= 0.83) (CBioportal), which suggests possible mechanisms 
by which HNF1B could exert the effects observed here – a 
control switch preventing EMT in non-tumor tissue. 
We have shown that HNF1B promoter methylation 
in PC is associated with known PC risk SNPs (Figure 2). 
Using 450K methylation array data from the Mayo Clinic 
[39, 40], we found a significant association between a 
linked OC risk SNP in HNF1B rs757210, and tumor 
methylation in n = 231 high-grade serous OC (Figure 
3B pink dots, and Supplementary Table 7). Although this 
specific variant was not associated with HNF1B expression 
levels in 182 HGS ovarian cancer samples (p = 0.2032) 
(Supplementary Table 8A), it was borderline significant 
in a much smaller set of 21 clear cell ovarian cancer 
patients (p = 0.0732) (Supplementary Table 8B) based on 
gene expression array data from samples genotyped as 
part of the Collaborative Oncological Gene-environment 
Study (COGS)[9]. However, we did identify a significant 
association between this SNP rs757210 and tumor 
methylation in HGS OC (Figure 3A and Supplementary 
Table 7), consistent with the report of Pharoah et al. 
(2013). TCGA data and fine-mapping of the region has 
previously identified two loci 6,8 kb apart, associated with 
increased promoter methylation in high-grade serous cases 
(rs7405776) and increased HNF1B expression in clear cell 
OC cases (rs11651755)[17], confirming our results: both 
of these SNPs - independent of each other - correlate with 
rs757210 (r2 = 0.6 and r2 = 0.97, respectively), which lies 
half-way between them. Furthermore, rs11651755 is also 
Table 1: Pair-wise estimates of LD between each of the five markers studied (r2; CEU population), confirming three 
distinct groupings of the SNPs studied.
rs11649743 rs757210 rs4430796 rs7501939 rs3760511
rs11649743 1 0.005 0.014 0.025 0.116
rs757210 1 0.543 0.739 0.163
rs4430796 1 0.764 0.337
rs7501939 1 0.257
rs3760511 1
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in strong LD with PC risk SNP rs4430796 (r2 = 0.97). 
There is an obvious overlap between regions of 
methylation within HNF1B in prostate and ovarian cancer 
tissues, with a methylation signal at the 3’-UTR in both. 
However, the most significant methylation occurs upstream 
of the TSS at the small CpG: 19 island and coincides with 
poised and active enhancers, identified by the presence of 
H3K27Ac, H3K4Me1 and H3K3Me3 histone marks [41]
(Figure 3Aii). Poised enhancers can be activated during 
differentiation or in response to external stimuli, and 
HNF1B is known to be important in embryonic urogenital 
development, where its role in EMT– as suggested by the 
sum of our functional data here – would be appropriate. 
However, if this role were disrupted by stressors typical 
of tumor cells, such as aberrant metabolism (a hallmark of 
cancer), HNF1B would then be tumor promoting. Indeed, 
the deregulation of pathways that maintain quiescence 
of ovarian surface epithelial cells has been shown to be 
instrumental in the progression to serous ovarian cancer 
[38], and would present this sort of insult. A similar 
effect has also been observed in renal cell carcinoma, 
where HNF1B expression correlated with malignant 
transformation and progression, with elevated levels of 
HNF1B expression in primary tumor associated with better 
prognosis [42]. Our findings highlight the multiple, small 
blocks of linkage disequilibrium within HNF1B, and may 
explain the complex associations observed at this locus 
between different risk SNP alleles, HNF1B expression and 
promoter methylation depending on cancer or histological 
subtype. 
Finally, to assess the phenotypic effects of HNF1B 
in the context of ovarian cancer, we over-expressed 
HNF1B in IOSE4 ovarian epithelial cells and tested typical 
tumor phenotypes: we observed significant effects on 
proliferation (Figure 5A), migration (5B) and invasiveness 
(Figure 5C) in IOSE4-HNF1B cells compared to IOSE4-
EV control cells. There is considerable evidence to 
indicate that HNF1B is over-expressed and behaves like 
an oncogene in clear cell OC [43], but is lost and acts as 
a tumor suppressor in HGS OC [44, 45]. Our data further 
support this. Similarly, our data suggests that that HNF1B 
may act as a tumor suppressor in benign prostate tissue, 
where it works normally to suppress classic features of 
tumorigenesis, by stimulating transcription of genes with 
clear roles in controlling cellular proliferation, adhesion 
and movement. On inactivation by DNA methylation 
in the progression to more aggressive tumors, these 
protective effects are lost.
DISCUSSION
HNF1B appears to play a significant role in the 
etiology and early stage neoplastic development of both 
prostate and ovarian cancers. We link intronic SNPs with 
HNF1B expression levels and epigenetic silencing in 
multiple populations in both prostate and ovarian cancers, 
thereby suggesting a plausible mechanism of action. 
In addition, our experimental data show that similar 
mechanisms contribute to prostate and serous ovarian 
cancer development and progression, and demonstrate the 
value of cross-site cancer analyses to functionally validate 
consistent GWAS findings across different disease types. 
In a clinical setting, the implication is that individuals 
carrying the high-risk genetic variants (rs11649743-G 
and rs3760511-G in prostate cancer; rs757210-G in 
serous ovarian cancer) are primed for EMT, which could 
be driven by additional stressors typical of tumor cells, 
such as aberrant metabolism – a hallmark of cancer. 
Most importantly, both increased transcript expression 
levels and reduced degree of promoter methylation are 
tagged by the same easily-screened genetic markers. The 
independent expression-methylation quantitative trait 
locus (eQTL-mQTL) associations identified here support 
the idea of pleiotropy as a common functional mechanism 
underlying the biology of neoplastic development at risk 
loci identified by GWAS. More comprehensive whole-
Figure 5: Over-expression of HNF1B in ovarian IOSE4 cells is associated with increased proliferation (5A), migration 
(5B) and invasion (5C) compared to IOSE4 cells expressing control GFP.
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genome eQTL-mQTL investigations may be informative 
for HNF1B specifically, as well as more generally for (epi)
genome-wide association studies (EWAS/GWAS) This 
finding further emphasizes the usefulness of considering 
disease mechanisms across distinct cancer types to 
describe a conserved and significant general mechanism 
of action.
MATERIALS AND METHODS
Patient samples
British prostate cancer and matched benign samples 
were taken from patients recruited under the Prostate 
Mechanisms for Progression and Treatment (ProMPT) 
study MREC 01/4/061, and have been previously 
described [46]. Ovarian cancer samples were taken 
from patients recruited into the OCAC consortium[9] 
at the Mayo Clinic, under approval of the Mayo Clinic 
Institutional Review, and have been previously described 
[9] [39, 40]. Danish prostate cancer and matched normal 
and adjacent normal samples were from patients recruited 
at Aarhus university hospital, under approval of the Aarhus 
University Regional Ethical committee and the Danish 
Data Protection Agency. 
All participants at each of the three study sites 
(Cambridge, Aarhus, Mayo Clinic) provided written 
informed consent; all experimental protocols at each of the 
three sites were approved by named local research ethics 
committees. All testing was undertaken in accordance with 
local, approved guidelines and regulations at each site.
Cell culture
PC3, DU145, and PNT2a cell lines were obtained 
from ATCC, and grown in RPMI supplemented with 10% 
FBS (Invitrogen) at 37C, 5% CO2. Stable PC3-HNF1B 
and DU145-HNF1B cell lines were grown under selection 
of 100 µg/ml geneticin (Gibco); PNT2a cells were grown 
under selection of 2 µg/ml puromycin (Invitrogen). IOSE4 
cells were grown under selection of 400 ng/ml puromycin. 
Stable cell lines over-expressing HNF1B
PC3 and DU145 cells were transfected with a 
modified rc/CMV vector to over-express HNF1B, to 
generate stable cell lines PC3-HNF1B and DU145-
HNF1B. PNT2a-HNF1B and OSE4-HNF1B cells were 
generated as described [17]. Parental cells were transfected 
with the corresponding empty vector (EV) or GFP as a 
control. 
siRNA
Cells were transfected with 50 nM siRNA with 
RNAi Max (Invitrogen) by reverse transfection, according 
to manufacturer’s instructions. HNF1B was silenced 
using 50 mM siRNAs SASI_Hs02_00302585 and SASI_
Hs02_00302586 in combination (Sigma). Universal 
negative control #1 (SIC001, Sigma) was used as a 
negative control. 
Western blots
Whole cell lysates were run on 4-16% SDS-PAGE 
gels (ThermoFisher) and transferred to PVDF membranes 
(Invitrogen). Antibodies used were: anti-HNF1B (H-85) 
(SC-22840, Santa Cruz), anti-B-actin (AC-15) (ab6276, 
Abcam), anti-paxillin [Y-113] (ab32084, Abcam), anti-
integrin α2 (611016, BB Biosciences), anti-integrin β1 
(610467, BD Biosciences).
Genotyping
British prostate samples were genotyped as 
part of the PRACTICAL consortium on custom SNP 
Illumina arrays (iCOGS)[47]. Danish prostate samples 
were genotyped using commercial TaqMan assays 
C___2559918_10 (rs11649743), C___2559889_10 
(rs4430796), C___2960803_10 (rs7501939) and 
C__26657407_10 (rs3760511). Ovarian samples were 
genotyped as part of the OCAC consortium using Illumina 
infinium iSelect BeadChips and iCOGS arrays[9]. 
Gene expression microarrays
Cell lines: Total RNA was harvested from 2 
biological replicates (4 technical replicates each) of 
PC3-EV and PC3-HNF1B cells (RiboPure, Ambion). 
UK clinical material: Total RNA was extracted from 
prostate tissue sections from fresh-frozen radical 
prostatectomy biopsies (AllPrep, Qiagen). Tumor or 
non-tumor was selected by pathologist A.Y.W. Danish 
clinical material: normal and cancer tissue sections were 
laser capture micro-dissected, RNA extracted and assayed 
on Affymetrix U133A gene expression arrays. See also 
Supplementary Methods.
Promoter methylation analysis
British prostate samples: gDNA was extracted 
from fresh, frozen radical prostatectomy tissue (AllPrep, 
Qiagen). Unmethylated cytosine bases were sodium 
bisulfite converted with EpiTect Bisulfite kits (Qiagen). 
Converted gDNA was amplified at HNF1B promoter 
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CpG islands using assay PM00178808 and PyroMark® 
kits (Qiagen). Methylation levels at each amplicon were 
determined using Pyrosequencing – see Supplementary 
Methods. Danish prostate samples: gDNA from 21 
Danish patient prostate cancer tumor samples (T), 12 
adjacent non-malignant prostate tissue (AN) and 9 normal 
prostate tissue (N) from patients with bladder cancer 
but no prostate cancer were assayed on Illumina 450K 
methylation arrays. Mayo Clinic ovarian cancer sample 
data were from 450K methylation arrays, generated as 
previously described [39, 40]. 
Chromatin immunoprecipitation
ChIP reactions were performed as described 
previously [48], using anti-HNF1B antibody (H-85) (SC-
22840, Santa Cruz. 
Data access
in vitro HNF1B over-expression gene expression 
assay data are entered at GEO under GSE63134.
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